Free shipping on all orders over $ 500


Cat.No.  Name Information
M10964 TPX-0046 TPX-0046 is a novel RET/SRC inhibitor that is used against RET in Ba/F3 cell proliferation assaysG810R The average IC50 is 17 nM.
M10933 GSK3179106 GSK3179106 is an orally active, selective RET kinase inhibitor for human and rat RET IC50 0.4 nM and 0.2 nM, respectively. GSK3179106 has the potential for use in irritable bowel syndrome (IBS) by reducing post-inflammatory and stress-induced visceral hypersensitivity reactions.
M10932 AST 487 AST 487 is a RET kinase inhibitor,IC50 880 nM, inhibits RET autophosphorylation, downstream effector activation, and also inhibits Flt-3,IC50 520 nM.
M10375 AD80 AD80 is a multikinase inhibitor, it potently targets human RET, BRAF, S6K, and SRC.
M9900 Selpercatinib (LOXO-292) Selpercatinib (LOXO-292) is a first-in-class, highly selective and potent small molecule RET inhibitor with good blood-brain barrier (BBB) penetration. and RET (G810R) with IC50 values of 14.0 nM, 24.1 nM and 530.7 nM, respectively.
M9346 Pralsetinib Pralsetinib (BLU-667) is a next generation highly potent, selective RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion.
M8146 RPI-1 RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
M49837 RET V804M-IN-1  RET V804M-IN-1 is a wt-RET -selective inhibitors of RETV804M kinase, with an IC50 of 20 nM.
M43523 Multi-kinase-IN-5 Multi-kinase-IN-5 is a promising multi-kinase inhibitory agent.
M43522 NSC194598 NSC194598 is a p53 DNA-binding inhibitor with IC50 value of 180 nM and 2-40 μM for in vitro and in vivo, respectively.
M43521 RET-IN-22 RET-IN-22 is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively.
M43520 RET-IN-23 RET-IN-23 is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively.
M39846 Pyrazoloadenine Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity.
M30921 BT44  BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus.
M29529 Enbezotinib  Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.
M29373 RET-IN-1  RET-IN-1 is a RET kinase inhibitor, with IC50 values of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
M21228 WF-47-JS03 WF-47-JS03 is a potent and selective RET kinase inhibitor with more than 500-fold selectivity for the kinase insertion domain receptor (KDR).WF-47-JS03 acts on Ba/F3 cells transfected with KIF5B-RET and LC-2/ad lung cancer cells transfected with CCDC6-RET with IC50s of 1.7 nM and 5.3 nM, respectively. crossed the blood-brain barrier.
M8536 SPP86 SPP86 is a potent cell permeable inihbitor of RET tyrosine kinase with an IC50 value of 8 nM and with some inhibitory activity at EphA1, FGFR1, Flt4, Lck and Yes.

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.